Kantarjian et al53 assessed the efficacy and protection of dasatinib, as compared with imatinib, for the very first-line procedure of CML-CP. 5 hundred and nineteen people with freshly diagnosed CML-CP were randomly assigned to receive dasatinib in a dose of a hundred mg at the time every day (259 patients) https://elagabalusn429din2.wikicarrier.com/user